Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#40 / 78 Total
ALZN - Alzamend Neuro Inc - Stock Price Chart
TickerALZN [NASD]
CompanyAlzamend Neuro Inc
CountryUSA
IndustryBiotechnology
Market Cap2.73MEPS (ttm)-27.58
P/E-EPS this Y89.05%
Forward P/E-EPS next Y24.22%
PEG-EPS past 5Y-11.45%
P/S-EPS next 5Y61.95%
P/B0.63EPS Q/Q95.01%
Dividend-Sales Q/Q-
Insider Own0.00%Inst Own1.25%
Insider Trans-Inst Trans53.83%
Short Float3.11%EarningsMar 13
Analyst Recom2.00Target Price180.00
Avg Volume147.80K52W Range3.16 - 135.54
May-13-25 08:00AM Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) -18.83%
07:30AM EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants (Benzinga)
May-08-25 08:00AM Alzamend Neuro Announces Reverse Stock Split (GlobeNewswire) -9.40%
May-07-25 08:00AM Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital (GlobeNewswire) -6.22%
07:31AM EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program (Benzinga)
Apr-08-25 09:55AM Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -5.24%
Mar-28-25 10:42AM Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-25-25 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-18-25 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital (GlobeNewswire) +5.03%
Mar-11-25 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AULT MILTON C IIIDirectorMay 12 '25Sale5.061,2136,1388,260May 14 05:00 PM
AULT MILTON C IIIDirectorMay 12 '25Sale5.2811581,843May 14 05:00 PM
Hyperscale Data, Inc.10% OwnerMay 12 '25Proposed Sale0.54516,090278,689May 09 07:49 PM
Horne William B.DirectorMar 26 '25Buy0.993,3343,28530,000Mar 27 07:30 AM
AULT MILTON C IIIDirectorMar 21 '25Buy1.022,9052,96985,273Mar 25 04:30 PM
GCTK - GlucoTrack Inc - Stock Price Chart
TickerGCTK [NASD]
CompanyGlucoTrack Inc
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap4.30MEPS (ttm)-57.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-18.33%
P/S-EPS next 5Y-
P/B0.53EPS Q/Q94.27%
Dividend-Sales Q/Q-
Insider Own2.46%Inst Own1.56%
Insider Trans0.00%Inst Trans388.67%
Short Float3.01%Earnings-
Analyst Recom-Target Price-
Avg Volume5.85M52W Range0.13 - 62.60
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.
OB - Outbrain Inc - Stock Price Chart
TickerOB [NASD, RUT]
CompanyOutbrain Inc
CountryUSA
IndustryInternet Content & Information
Market Cap268.75MEPS (ttm)-0.74
P/E-EPS this Y402.17%
Forward P/E3.92EPS next Y81.02%
PEG-EPS past 5Y22.72%
P/S0.28EPS next 5Y119.92%
P/B0.57EPS Q/Q-587.68%
Dividend-Sales Q/Q31.98%
Insider Own68.95%Inst Own17.90%
Insider Trans-0.12%Inst Trans3.55%
Short Float5.84%EarningsMay 09/b
Analyst Recom2.20Target Price5.33
Avg Volume458.82K52W Range2.81 - 7.87
Outbrain, Inc. engages in the development and operation of a recommendation platform powering the open web. Its platform brings online, mobile, and video content to audiences while helping publishers understand their audiences through data. It operates through the following segment: USA, Europe, The Middle East and Africa, and Others. The company was founded by Yaron Michael Galai and Ori Lahav in 2006 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kostman DavidChief Executive OfficerMar 13 '25Buy3.9820,00079,600828,940Mar 17 04:57 PM
Bradshaw WenkaiCAO & SVP Corporate ControllerMar 07 '25Option Exercise0.003,1500111,124Mar 11 07:16 PM
Kostman DavidChief Executive OfficerMar 07 '25Option Exercise0.00200,0000854,474Mar 11 07:16 PM
Kiviat JasonChief Financial OfficerMar 07 '25Option Exercise0.007,2000205,261Mar 11 07:16 PM
Porat AsafChief Operating OfficerMar 07 '25Option Exercise0.0018,0000528,300Mar 11 07:15 PM
CTKB - Cytek BioSciences Inc - Stock Price Chart
TickerCTKB [NASD, RUT]
CompanyCytek BioSciences Inc
CountryUSA
IndustryMedical Devices
Market Cap338.18MEPS (ttm)-0.09
P/E-EPS this Y-178.21%
Forward P/E-EPS next Y57.53%
PEG-EPS past 5Y18.28%
P/S1.72EPS next 5Y-
P/B0.90EPS Q/Q-88.54%
Dividend-Sales Q/Q-7.59%
Insider Own9.61%Inst Own60.70%
Insider Trans0.00%Inst Trans-1.58%
Short Float3.66%EarningsMay 08/a
Analyst Recom2.67Target Price5.60
Avg Volume837.31K52W Range2.60 - 7.63
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
HEPA - Hepion Pharmaceuticals Inc - Stock Price Chart
TickerHEPA [NASD]
CompanyHepion Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap1.20MEPS (ttm)-109.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y55.44%
P/S-EPS next 5Y-
P/B-EPS Q/Q90.82%
Dividend-Sales Q/Q-
Insider Own0.48%Inst Own0.28%
Insider Trans0.00%Inst Trans315.92%
Short Float4.12%Earnings-
Analyst Recom3.00Target Price1100.00
Avg Volume4.82M52W Range0.11 - 68.00
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
VERO - Venus Concept Inc - Stock Price Chart
TickerVERO [NASD]
CompanyVenus Concept Inc
CountryCanada
IndustryMedical Devices
Market Cap3.13MEPS (ttm)-76.26
P/E-EPS this Y71.31%
Forward P/E-EPS next Y75.47%
PEG-EPS past 5Y38.15%
P/S0.05EPS next 5Y-
P/B0.69EPS Q/Q5.66%
Dividend-Sales Q/Q-21.95%
Insider Own74.64%Inst Own0.84%
Insider Trans-3.87%Inst Trans-27.39%
Short Float11.53%EarningsMay 15/b
Analyst Recom3.00Target Price116.60
Avg Volume1.21M52W Range2.16 - 17.49
Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Natale AnthonyDirectorDec 03 '24Sale0.3142,76813,1940Dec 04 05:43 PM
Masters Michael Willingham10% OwnerOct 01 '24Sale0.60140,21483,45519,203Oct 02 07:54 PM
Masters Michael Willingham10% OwnerOct 02 '24Sale0.5394,55350,16017,059Oct 02 07:54 PM
Masters Michael Willingham10% OwnerSep 30 '24Sale0.6471,36846,02522,383Oct 02 07:54 PM
Masters Michael Willingham10% OwnerJun 07 '24Sale1.21387,231467,0390Jun 12 04:06 PM
XFOR - X4 Pharmaceuticals Inc - Stock Price Chart
TickerXFOR [NASD, RUT]
CompanyX4 Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap16.90MEPS (ttm)2.24
P/E1.30EPS this Y-81.49%
Forward P/E-EPS next Y16.43%
PEG0.03EPS past 5Y47.41%
P/S0.54EPS next 5Y50.77%
P/B0.74EPS Q/Q100.53%
Dividend-Sales Q/Q-
Insider Own33.77%Inst Own30.84%
Insider Trans-9.75%Inst Trans-
Short Float7.59%EarningsMay 01/b
Analyst Recom1.00Target Price42.67
Avg Volume91.98K52W Range2.98 - 33.90
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Baldry MarkChief Commercial OfficerMay 17 '24Buy0.6821,64614,654115,769Feb 14 04:08 PM
Baldry MarkChief Commercial OfficerNov 15 '24Buy0.3413,4044,598129,173Feb 14 04:08 PM
Ragan PaulaPresident and CEOJan 24 '25Sale0.4576,47334,7191,087,386Jan 27 06:15 PM
Mostafa Adam S.Chief Financial OfficerJan 24 '25Sale0.4574,77333,9470Jan 27 06:15 PM
Baldry MarkChief Commercial OfficerJan 24 '25Sale0.4529,15913,24194,123Jan 27 06:15 PM
HYPR - Hyperfine Inc - Stock Price Chart
TickerHYPR [NASD]
CompanyHyperfine Inc
CountryUSA
IndustryMedical Devices
Market Cap48.36MEPS (ttm)-0.55
P/E-EPS this Y18.75%
Forward P/E-EPS next Y12.09%
PEG-EPS past 5Y11.81%
P/S4.12EPS next 5Y12.90%
P/B1.12EPS Q/Q9.13%
Dividend-Sales Q/Q-35.14%
Insider Own25.59%Inst Own10.87%
Insider Trans-0.03%Inst Trans4.82%
Short Float2.40%EarningsMay 13/a
Analyst Recom2.00Target Price0.98
Avg Volume1.08M52W Range0.58 - 1.90
Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TEISSEYRE THOMASChief Operating OfficerFeb 18 '25Sale1.203,2373,88484,990Feb 18 07:03 PM
TEISSEYRE THOMASChief Operating OfficerNov 18 '24Sale0.852,8002,38088,227Nov 18 05:41 PM
TEISSEYRE THOMASChief Operating OfficerAug 16 '24Sale1.052,7462,88391,027Aug 16 05:04 PM
NFE - New Fortress Energy Inc - Stock Price Chart
TickerNFE [NASD]
CompanyNew Fortress Energy Inc
CountryUSA
IndustryOil & Gas Midstream
Market Cap729.32MEPS (ttm)-2.26
P/E-EPS this Y13.66%
Forward P/E-EPS next Y6.06%
PEG-EPS past 5Y5.11%
P/S0.34EPS next 5Y-10.63%
P/B0.42EPS Q/Q-383.27%
Dividend2.51%Sales Q/Q-31.84%
Insider Own35.06%Inst Own70.72%
Insider Trans0.32%Inst Trans62.29%
Short Float28.59%EarningsMay 14/a
Analyst Recom2.00Target Price10.33
Avg Volume8.71M52W Range2.32 - 27.65
New Fortress Energy, Inc. is a holding company engaged in the management of integrated gas-to-power energy infrastructure. It funds, builds, and operates natural gas infrastructure and logistics to deliver energy solutions. The company was founded by Wesley Robert Edens on February 25, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shin YunyoungChief Accounting OfficerJan 02 '25Option Exercise0.0080,4550128,115Apr 23 05:30 PM
Guinta Christopher S.Chief Financial OfficerMar 13 '25Buy8.575,00042,850206,653Mar 13 12:15 PM
EDENS WESLEY RChief Executive OfficerMar 12 '25Buy9.07100,000907,00036,021,915Mar 12 12:22 PM
EDENS WESLEY RChief Executive OfficerMar 11 '25Buy8.77200,0001,754,00035,921,915Mar 11 01:21 PM
EDENS WESLEY RChief Executive OfficerOct 01 '24Buy8.635,793,74249,999,99335,721,915Oct 03 06:13 PM
SNCR - Synchronoss Technologies Inc - Stock Price Chart
TickerSNCR [NASD]
CompanySynchronoss Technologies Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap80.03MEPS (ttm)-0.22
P/E-EPS this Y18.20%
Forward P/E2.40EPS next Y50.26%
PEG-EPS past 5Y-
P/S0.46EPS next 5Y-
P/B2.26EPS Q/Q-264.27%
Dividend-Sales Q/Q-1.75%
Insider Own11.96%Inst Own48.76%
Insider Trans-2.53%Inst Trans-0.64%
Short Float1.17%EarningsMay 06/a
Analyst Recom1.00Target Price24.33
Avg Volume98.04K52W Range7.13 - 15.46
Synchronoss Technologies, Inc. engages in the provision of cloud and enterprise solutions. The firm offers software-based activation for connected devices globally. Its platform includes cloud home, personal cloud content transfer and out-of-box experience, advance messaging and email suite, journey creation and advisor, digital coach, digital portal, activation, Internet of Things (IoT), and smart buildings. The company was founded by James M. McCormick and Stephen G. Waldis in 2000 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Jeffrey GeorgeChief Executive OfficerMay 01 '25Sale10.226,28964,280445,564May 02 08:18 PM
Doran Patrick JosephEVP & Chief Technology OfficerApr 28 '25Sale10.681,75118,701168,436May 01 07:57 PM
Gabrys ChristinaEVP and Chief Legal OfficerApr 28 '25Sale10.688829,42074,246May 01 07:57 PM
Miller Jeffrey GeorgeOfficerMay 01 '25Proposed Sale10.226,28964,278May 01 03:18 PM
Gabrys ChristinaOfficerApr 28 '25Proposed Sale10.688829,420Apr 28 04:11 PM
12345678